[Form 4] CYTOKINETICS INC Insider Trading Activity

Rhea-AI Filing Summary

CYTOKINETICS INC EVP of R&D Fady Malik reported tax-related stock sales. On the reported date, he sold a total of 12,033 shares of common stock in open-market transactions at $62.15 per share.

Footnotes state these were company-compelled sell-to-cover transactions to satisfy tax withholding obligations from RSU vesting, indicating they were driven by taxes rather than discretionary selling. After the transactions, he continued to hold 153,902 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		7,636	D	$62.15	158,299	D
Common Stock	03/17/2026		S(2)		4,397	D	$62.15	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

2. Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CYTOKINETICS (CYTK) EVP Fady Malik report in this Form 4?

He reported selling 12,033 shares of CYTOKINETICS common stock in open-market transactions at $62.15 per share. The sales were disclosed as part of a company-compelled sell-to-cover process related to tax withholding on recently vested RSUs.

Were Fady Malik’s CYTOKINETICS (CYTK) share sales discretionary?

The sales were described as company-compelled sell-to-cover transactions to satisfy tax withholding on RSU vesting. This indicates the activity was primarily driven by tax obligations, not by a discretionary decision to reduce his investment position in CYTOKINETICS.

How many CYTOKINETICS (CYTK) shares does Fady Malik hold after the sales?

Following the reported transactions, Fady Malik directly holds 153,902 shares of CYTOKINETICS common stock. This remaining stake is significantly larger than the 12,033 shares sold to cover tax withholding related to the vesting of restricted stock units.

What price did Fady Malik’s CYTOKINETICS (CYTK) shares sell for?

The reported sales occurred at an average price of $62.15 per share. These open-market transactions were executed as part of a company-compelled sell-to-cover arrangement tied to tax withholding requirements on recently vested restricted stock units.

What is a company-compelled sell-to-cover transaction for CYTOKINETICS (CYTK) insiders?

A company-compelled sell-to-cover transaction involves automatically selling enough shares to pay required tax withholding when RSUs vest. For CYTOKINETICS, the filing states Malik’s sales were made for this purpose rather than as discretionary open-market selling of his holdings.